- Trials with a EudraCT protocol (94)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
94 result(s) found for: Cardiac fibrosis.
Displaying page 1 of 5.
EudraCT Number: 2017-002914-30 | Sponsor Protocol Number: LCZ696-17 | Start Date*: 2017-11-06 |
Sponsor Name:FIMABIS | ||
Full Title: LCZ696 in heart failure patients with reduced ejection fraction and high comorbidity: effect on left ventricular remodeling and fibrosis assessed by novel heart failure biomarkers and cardiac magne... | ||
Medical condition: Chronic heart failure NYHA class II-IV with reduced ejection fraction (EF =< 40%) and elevated NT-proBNP ≥ 600 pg/mL, but 400 pg/mL if hospitalized for heart failure within 12 months | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002455-26 | Sponsor Protocol Number: IRON-CMR | Start Date*: 2014-09-20 |
Sponsor Name:Karolinska Institute | ||
Full Title: The use of intravenous Iron oxide as a contrast agent for cardiac magnetic resonance imaging. | ||
Medical condition: Cardiovascular diseases: Acute myocardial infarction, chronic myocardial infarction, myocardial ischemia, myocarditis, diffuse myocardial fibrosis. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001659-10 | Sponsor Protocol Number: S55481 | Start Date*: 2013-08-08 | |||||||||||
Sponsor Name:UZLeuven | |||||||||||||
Full Title: Acute effects of Sildenafil on the hemodynamics, Right Ventricle performance and cyclic GMP concentration in Heart failure patients with preserved left ventricular ejection fraction and patients af... | |||||||||||||
Medical condition: To investigate acute effects of sildenafil on cardiac hemodynamics, right ventricle performance and cGMP concentrations in heart failure patients with preserved ejection fraction and patients after... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002464-75 | Sponsor Protocol Number: 534 | Start Date*: 2022-12-06 | |||||||||||
Sponsor Name:Groupe Hospitalier Paris Saint-Joseph | |||||||||||||
Full Title: Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial | |||||||||||||
Medical condition: Acute exacerbation of idiopathic pulmonary fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003146-75 | Sponsor Protocol Number: BETA3_LVH | Start Date*: 2016-03-14 | |||||||||||
Sponsor Name:Université catholique de Louvain (UCL) | |||||||||||||
Full Title: A multi-centre randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on the progression of left ventricular mass and diastolic function in patients with struct... | |||||||||||||
Medical condition: Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) PT (Completed) GR (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004823-21 | Sponsor Protocol Number: PBI-4050-CT-9-10 | Start Date*: 2017-10-25 | |||||||||||
Sponsor Name:Prometic Biosciences Inc. | |||||||||||||
Full Title: An Open-Label Rollover Study of PBI-4050 in Subjects with Alström Syndrome | |||||||||||||
Medical condition: Alström Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000222-35 | Sponsor Protocol Number: 2017-000222-35 | Start Date*: 2017-07-21 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients – a randomized controlled trial | ||
Medical condition: Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019802-17 | Sponsor Protocol Number: 205.438 | Start Date*: 2010-09-13 |
Sponsor Name:Boehringer Ingelheim France | ||
Full Title: A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 μg administered once daily via the Respimat® device in pati... | ||
Medical condition: Cystic Fibrosis | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PT (Completed) HU (Completed) FR (Completed) SK (Completed) DE (Completed) GB (Completed) BE (Completed) CZ (Completed) IT (Completed) AT (Completed) IE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004498-34 | Sponsor Protocol Number: SUM | Start Date*: 2016-12-12 | |||||||||||
Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||
Full Title: Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodie... | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004497-15 | Sponsor Protocol Number: ERGO | Start Date*: 2016-12-12 | |||||||||||
Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||
Full Title: Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in C... | |||||||||||||
Medical condition: Cushing’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003179-12 | Sponsor Protocol Number: MN0511_1 | Start Date*: 2012-01-09 |
Sponsor Name:University Hospital of Wuerzburg, Medical Director | ||
Full Title: Mineralocorticoid Receptor antagonists in End stage reNal DiseAse | ||
Medical condition: Hemodialysis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000295-42 | Sponsor Protocol Number: GFT505-212-7 | Start Date*: 2012-09-11 | |||||||||||
Sponsor Name:GENFIT | |||||||||||||
Full Title: A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH). | |||||||||||||
Medical condition: Patients with Non-Alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) ES (Completed) GB (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000077-39 | Sponsor Protocol Number: RECOGITO_V1.0_2014 | Start Date*: 2014-02-27 | |||||||||||||||||||||
Sponsor Name:Sapienza University of Rome | |||||||||||||||||||||||
Full Title: Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phospho... | |||||||||||||||||||||||
Medical condition: Diabetic Cardiomyopathy, Diabetes Mellitus Type 2, Left Ventricular Hypertrophy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002020-25 | Sponsor Protocol Number: 052017 | Start Date*: 2018-08-31 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: ANGIOTENSIN–NEPRILYSIN INHIBITION IN DIASTOLIC DYSFUNCTION AFTER AMI | |||||||||||||
Medical condition: Diastolic dysfunction after acute myocardial infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006611-68 | Sponsor Protocol Number: shey01.2006 | Start Date*: 2007-05-07 |
Sponsor Name:academic hospital Maastricht | ||
Full Title: Valsartan on top of standard therapy as a novel therapeutic strategy to treat cardiac dysfunction in patients with infammatory cardiomyopathies | ||
Medical condition: patients suffering from heartfailure and inflammatory cardiomyopthies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003497-48 | Sponsor Protocol Number: EMPATHY | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial | |||||||||||||
Medical condition: acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001446-14 | Sponsor Protocol Number: N/GF-TORAFIC-06 | Start Date*: 2006-10-11 | |||||||||||
Sponsor Name:NOVAG S.A., FERRER GRUPO | |||||||||||||
Full Title: Multicenter parallel-group, concealed and randomized allocation and blinded-endpoint study, to evaluate the effects of Torasemide PR versus furosemide on a biochemical marker of collagen synthesis ... | |||||||||||||
Medical condition: Heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002823-16 | Sponsor Protocol Number: 02-2011 | Start Date*: 2011-07-27 | |||||||||||
Sponsor Name:A.O. UNIVERSITARIA INTEGRATA DI VERONA | |||||||||||||
Full Title: Effects of Vitamin D in patients affected by heart failure | |||||||||||||
Medical condition: Heart failure is a condition that occurs when the heart loses its normal ability to pump blood to maintain vital body functions and, therefore, works with lower efficiency. Several studies have sho... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002632-24 | Sponsor Protocol Number: P160915 | Start Date*: 2018-11-13 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: Therapeutic plasma exchange, rituximab and intravenous immunoglobulins (IVIg) for severe acute exacerbation of idiopathic pulmonary fibrosis admitted in ICU: an open, randomized, controlled trial | ||
Medical condition: severe acute exacerbation of idiopathic pulmonary fibrosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003601-25 | Sponsor Protocol Number: DROP-PIP | Start Date*: 2014-03-28 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Hear... | ||
Medical condition: Diastolic heart failure and diabetes mellitus type II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
